Juan-Pablo Mas

Med and AI Tech in Focus   Smart Bandage Detects Inflammation and Infection Researchers at California Institute of Technology have developed a smart bandage called iCares that continuously monitors fluids in wound sites in real time to assess inflammation and infection. The bandage is equipped with three different microfluidic components. One removes moisture from the wound to help with healing. Another detects nitric oxide and other molecules that indicate wound inflammation. A third component detects hydrogen peroxide, which is another biomarker of infection which occurs one to three days before patients experience symptoms. The iCares bandage was designed for patients with chronic wounds that are slow to heal, because of diabetes or poor blood flow at the wound site. iCares is composed of a flexible strip that can be 3-d printed and incorporates a disposable biomarker sensor array together with reusable circuit board that handles signal processing and wireless data transmission. A machine learning algorithm is used to classify and monitor any changes in patients’ wounds in real-time and can send a signal and data to a Smartphone. VC Investors are always adjusting their "Play Book" with a variety of options for investing. Mikal Ventures is one of those alternatives, offering curated solutions to real world problems. Reach out if you have questions on how we can be of assistance and bookmark https://mikalventures.com/ for additional insights and information.

1

Med and AI Tech in Focus   Smart Bandage Detects Inflammation and Infection Researchers at California Institute of Technology have developed a smart bandage called iCares that continuously monitors fluids in wound sites in real time to assess inflammation and infection. The bandage is equipped with three different microfluidic components. One removes moisture from the wound to help with healing. Another detects nitric oxide and other molecules that indicate wound inflammation. A third component detects hydrogen peroxide, which is another biomarker of infection which occurs one to three days before patients experience symptoms. The iCares bandage was designed for patients with chronic wounds that are slow to heal, because of diabetes or poor blood flow at the wound site. iCares is composed of a flexible strip that can be 3-d printed and incorporates a disposable biomarker sensor array together with reusable circuit board that handles signal processing and wireless data transmission. A machine learning algorithm is used to classify and monitor any changes in patients’ wounds in real-time and can send a signal and data to a Smartphone. VC Investors are always adjusting their "Play Book" with a variety of options for investing. Mikal Ventures is one of those alternatives, offering curated solutions to real world problems. Reach out if you have questions on how we can be of assistance and bookmark https://mikalventures.com/ for additional insights and information.

4

Israeli MedTech: Restore Medical secures $23M Series B to push forward novel heart failure therapy The new funding will allow the Israeli startup to complete an ongoing feasibility study in Europe, where early results have shown what the company describes as encouraging long-term safety and efficacy data. Amongst the challenges of building a medical device company, fundraising, and global dynamics, it is a blessing to be able to watch Gilad Marom and team continue to succeed with their development! https://lnkd.in/eNjvg2cd

45

2 Comments

Check out the latest from Limbic - their breakthrough study in Nature Portfolio, shows how Limbic turns frontier language models into behavioral health specialists. In their pre-registered, double-blind randomized trial they showed that: 1️⃣ Adding the Limbic Layer improves AI-led therapy performance by 43% 2️⃣ Clinicians preferred Limbic over general-purpose LLMs 83% of the time 3️⃣ 74% of Limbic's AI sessions ranked among the top 10% of therapists 4️⃣ Patients rate the Limbic experience as comparable to clinician-led sessions Amazing stuff from Ross Harper and Sebastiaan de Vries - delighted to have them in the Entrepreneurs First portfolio.

49

1 Comment

I turn down 99% of non-profit board and advisory requests. Digitalis Commons is the 1%. They're not just talking about bridging the digital divide. They're building the infrastructure to actually do it. Their mission: ensuring every American has access to the digital tools and skills that define opportunity in 2025. Not someday. Now. What convinced me to join as Expert in Residence: • Real impact metrics, not vanity statistics • Technology-first approach to scaling solutions • Focus on underserved communities where the need is greatest • Leadership that measures success by lives changed, not dollars raised As someone who's spent years at the intersection of AI, healthcare, and deep tech, I see how the digital divide compounds every other inequality. Healthcare access. Educational opportunity. Economic mobility. They all require digital literacy now. The best non-profits don't ask for your time. They earn it through impact. Digitalis Commons earned mine. To the team: Lara Mangravite, Cierra Crowder-Lopez, Sia Anagnostou, Janice Louie, Justin Levy, Idin Jafari Jack McGee, Sarah Valentine, Geoffrey Smith, Misti Ushio, Brian Trelstad, Jennifer Friel Goldstein, excited to roll up our sleeves and build something that matters. Let's bridge this divide one community at a time. Because serving your country isn't just about what you build in the private sector. It's about ensuring everyone has the tools to build their own future. #DigitalEquity #NonProfit #TechForGood #SocialImpact #CommunityDevelopment

60

4 Comments

Big News at Pack Ventures 🚀🐺🧬 We’re thrilled to welcome two outstanding Venture Partners to the Pack Ventures team! Jenny Cronin, PhD and William Canestaro, PhD are two of the most respected and well-connected figures in the Seattle biotech landscape. They strengthen our mission of building the leading pre-seed biotech fund in Seattle—a city we believe is one of the most important biotech markets in the world for the convergence of A.I. and Biotech! Seattle isn’t just home to world-class institutions like the Institute for Protein Design, University of Washington, Fred Hutch, and Seattle Children's —it’s also a global hub where AI and biotech converge. From David Baker’s recent #NobelPrize to the cutting-edge work coming out of the Paul G. Allen School of Computer Science & Engineering, Microsoft, Amazon, and the Allen Institute and Ai2 , the depth of A.I. talent here is extraordinary. At Pack Ventures, we’re doubling down on the Seattle and UW innovation ecosystem. Our belief is simple: the next generation of industry-defining biotech companies will be built here—and we’re here to help founders make that future a reality. With our new Venture Partners on board, we’re better equipped than ever to support early-stage founders transforming science into scalable solutions. #Biotech #VentureCapital #AIxBio #SeattleInnovation #PackVentures #UWSpinouts #TechBio

369

33 Comments

Tarek Mouhieddine M.D. and I are excited to announce that POM Health is coming out of stealth today and opening a limited beta to early customers. We were founded with a simple mission of catching as many cancers as possible as early as possible and upgrading a cancer screening paradigm that too often catches disease late.  In the U.S., screening catches just ~14% of cancer cases, and around half of diagnoses are made at Stage III+. Despite having world-class detection technologies, we routinely screen for just 5 out of 200+ cancer types, often at multi-year intervals between screens, and most people won’t interact with an oncologist until there’s already a high suspicion of cancer. The result: 625k+ deaths from cancer annually in the US, 70% of which are in cancers without guideline-recommended screening, and far too many people believe their annual physical is an effective warning system. Elite cancer centers around the world (like where Tarek practices) have made significant advances in cancer detection and interception that have not yet translated to our primary care and insurance-driven screening system. With AI, we can now bring these advances to millions. Through POM Health, we offer access to more comprehensive cancer screening. Screening is led by world class oncologists, powered by AI, and accessible via telehealth, with one-time and annual subscription offerings.   POM's cancer screens use multiple detection modalities (including sample-based biomarkers, MCED, imaging, and genetics) to provide broad coverage across 90%+ of cancers, with overlapping coverage for 80%+. When a cancer signal is detected, your POM oncologist drives the next step quickly. The lifetime risk of acquiring cancer stands at 39% in the US and early onset cancers have doubled since 1990. Cancer isn't a rare disease and we believe people should have an option to mitigate their cancer risk.  Now serving beta test users in: MA, NY, and FL (CA soon, and waitlist open for all other states) Learn more: https://lnkd.in/e9qcaru9 Questions: lucas@pomhealth.xyz or tarek@pomhealth.xyz (POM = Peace of Mind, which everyone deserves when it comes to cancer) Thanks also to our first investor Leo Korsunsky!

42

8 Comments

Behind every #FDA clearance is a founder who refused to take *NO* for an answer. 🧬🚀 Last month, two! of our portfolio companies reached major regulatory milestones: Hypervision Surgical received FDA 510(k) clearance for its HYPERSNAP® system - the first surgical platform to combine Hyperspectral Imaging with AI-powered analytics for intraoperative decision support. Hilo by Aktiia secured FDA OTC clearance for the Hilo Band - the world’s first cuffless blood pressure monitor approved for over-the-counter use in the US. No cuff. No prescription. Just clinical-grade blood pressure data from the wrist. And with tackling hypertension they were going after one of the biggest global health challenges. Both breakthroughs reflect what we look for at redalpine: long-term commitment to science, and ambition to reimagine healthcare from first principles. As Josep Solà, co-founder and CTO at Hilo by Aktiia, put it: “𝘖𝘶𝘳 𝘨𝘰𝘢𝘭 𝘸𝘢𝘴 𝘤𝘭𝘦𝘢𝘳 𝘧𝘳𝘰𝘮 𝘵𝘩𝘦 𝘣𝘦𝘨𝘪𝘯𝘯𝘪𝘯𝘨: 𝘵𝘰 𝘤𝘳𝘦𝘢𝘵𝘦 𝘢 𝘱𝘳𝘰𝘥𝘶𝘤𝘵 𝘵𝘩𝘢𝘵 𝘸𝘰𝘶𝘭𝘥 𝘣𝘦 𝘶𝘴𝘦𝘥 𝘢𝘴 𝘪𝘯𝘵𝘶𝘪𝘵𝘪𝘷𝘦𝘭𝘺 𝘢𝘯𝘥 𝘦𝘧𝘧𝘰𝘳𝘵𝘭𝘦𝘴𝘴𝘭𝘺 𝘢𝘴 𝘢 𝘴𝘮𝘢𝘳𝘵𝘱𝘩𝘰𝘯𝘦. 𝘉𝘶𝘵 𝘣𝘦𝘩𝘪𝘯𝘥 𝘵𝘩𝘢𝘵 𝘴𝘪𝘮𝘱𝘭𝘪𝘤𝘪𝘵𝘺, 𝘵𝘩𝘦 𝘥𝘦𝘷𝘪𝘤𝘦 𝘸𝘰𝘶𝘭𝘥 𝘨𝘦𝘯𝘦𝘳𝘢𝘵𝘦 𝘤𝘭𝘪𝘯𝘪𝘤𝘢𝘭𝘭𝘺 𝘢𝘤𝘤𝘶𝘳𝘢𝘵𝘦 𝘣𝘭𝘰𝘰𝘥 𝘱𝘳𝘦𝘴𝘴𝘶𝘳𝘦 𝘥𝘢𝘵𝘢, 𝘧𝘪𝘵 𝘧𝘰𝘳 𝘮𝘦𝘥𝘪𝘤𝘢𝘭 𝘥𝘦𝘤𝘪𝘴𝘪𝘰𝘯-𝘮𝘢𝘬𝘪𝘯𝘨.” That required more than just science. “𝘛𝘩𝘦 𝘵𝘳𝘶𝘦 𝘨𝘢𝘵𝘦𝘬𝘦𝘦𝘱𝘦𝘳 𝘵𝘰 𝘵𝘩𝘢𝘵 𝘷𝘪𝘴𝘪𝘰𝘯? 𝘕𝘰𝘵 𝘫𝘶𝘴𝘵 𝘧𝘶𝘯𝘥𝘪𝘯𝘨. 𝘕𝘰𝘵 𝘫𝘶𝘴𝘵 𝘵𝘦𝘢𝘮. 𝘕𝘰𝘵 𝘦𝘷𝘦𝘯 𝘶𝘴𝘦𝘳 𝘢𝘥𝘰𝘱𝘵𝘪𝘰𝘯. 𝘐𝘵 𝘸𝘢𝘴, 𝘢𝘯𝘥 𝘴𝘵𝘪𝘭𝘭 𝘪𝘴, 𝘳𝘦𝘨𝘶𝘭𝘢𝘵𝘰𝘳𝘺 𝘢𝘱𝘱𝘳𝘰𝘷𝘢𝘭.” Hypervision Surgical’s approach was equally strategic. For CEO and co-founder Michael Ebner, early alignment with the FDA was a key part of their roadmap: “𝘐𝘯𝘪𝘵𝘪𝘢𝘵𝘦 𝘦𝘯𝘨𝘢𝘨𝘦𝘮𝘦𝘯𝘵 𝘸𝘪𝘵𝘩 𝘵𝘩𝘦 𝘍𝘋𝘈 𝘢𝘴 𝘦𝘢𝘳𝘭𝘺 𝘢𝘴 𝘱𝘰𝘴𝘴𝘪𝘣𝘭𝘦 - 𝘪𝘥𝘦𝘢𝘭𝘭𝘺 𝘪𝘯 𝘱𝘢𝘳𝘢𝘭𝘭𝘦𝘭 𝘸𝘪𝘵𝘩 𝘥𝘦𝘷𝘦𝘭𝘰𝘱𝘪𝘯𝘨 𝘢 𝘷𝘪𝘢𝘣𝘭𝘦, 𝘦𝘷𝘰𝘭𝘷𝘪𝘯𝘨 𝘤𝘰𝘮𝘮𝘦𝘳𝘤𝘪𝘢𝘭 𝘴𝘵𝘳𝘢𝘵𝘦𝘨𝘺. 𝘛𝘩𝘢𝘵 𝘦𝘢𝘳𝘭𝘺 𝘥𝘪𝘢𝘭𝘰𝘨𝘶𝘦 𝘩𝘦𝘭𝘱𝘴 𝘳𝘦𝘥𝘶𝘤𝘦 𝘶𝘯𝘤𝘦𝘳𝘵𝘢𝘪𝘯𝘵𝘺 𝘢𝘯𝘥 𝘢𝘤𝘤𝘦𝘭𝘦𝘳𝘢𝘵𝘦𝘴 𝘦𝘷𝘦𝘳𝘺𝘵𝘩𝘪𝘯𝘨 𝘥𝘰𝘸𝘯𝘴𝘵𝘳𝘦𝘢𝘮.” He also encourages founders to explore fast-track pathways: “𝘊𝘰𝘯𝘴𝘪𝘥𝘦𝘳 𝘱𝘳𝘰𝘨𝘳𝘢𝘮𝘴 𝘭𝘪𝘬𝘦 𝘵𝘩𝘦 𝘍𝘋𝘈’𝘴 𝘚𝘛𝘦𝘗 (𝘚𝘢𝘧𝘦𝘳 𝘛𝘦𝘤𝘩𝘯𝘰𝘭𝘰𝘨𝘪𝘦𝘴 𝘗𝘳𝘰𝘨𝘳𝘢𝘮) 𝘰𝘳 𝘉𝘳𝘦𝘢𝘬𝘵𝘩𝘳𝘰𝘶𝘨𝘩 𝘋𝘦𝘷𝘪𝘤𝘦𝘴 𝘋𝘦𝘴𝘪𝘨𝘯𝘢𝘵𝘪𝘰𝘯 (𝘉𝘋𝘋). 𝘛𝘩𝘦𝘴𝘦 𝘦𝘯𝘤𝘰𝘶𝘳𝘢𝘨𝘦 𝘰𝘯𝘨𝘰𝘪𝘯𝘨, 𝘱𝘳𝘰𝘢𝘤𝘵𝘪𝘷𝘦 𝘤𝘰𝘮𝘮𝘶𝘯𝘪𝘤𝘢𝘵𝘪𝘰𝘯 𝘢𝘯𝘥 𝘤𝘢𝘯 𝘩𝘦𝘭𝘱 𝘧𝘢𝘴𝘵-𝘧𝘰𝘳𝘸𝘢𝘳𝘥 𝘵𝘩𝘦 𝘳𝘦𝘨𝘶𝘭𝘢𝘵𝘰𝘳𝘺 𝘵𝘪𝘮𝘦𝘭𝘪𝘯𝘦.” Congratulations to Josep Solà, Michael Ebner, and both incredible teams. This is what #empoweringGameChangers looks like. #FDA #HealthTech #Wearables #Surgery #DigitalHealth #Hypertension #MedicalDevices #VentureCapital #redalpine

141

9 Comments

We’re thrilled to be collaborating with Intermountain Health and Dr. West on this groundbreaking initiative. Together, we’re advancing the development of an ambient, non-intrusive vocal assessment solution that leverages Canary Speech’s patented vocal biomarker technology. This work aims to enhance clinical decision support by enabling real-time insights through everyday speech—bringing us closer to a future where voice becomes a powerful window into health and wellness.

28

3 Comments

In the context of MedTech innovation, research often relies on proprietary data from private companies. Can a study using such data truly be "scientific" if the data-generation process and raw data cannot be made public? I think the statement from King, Keohane, and Verba (Princeton University Press, 1994) that research procedures must be "explicit, codified, and public" is profoundly thought-provoking for venture investment in the scientific valuation process in the MedTech sector. While intellectual property (IP) protection and non-disclosure agreements are critical to a startup's secret sauce, they create direct tension with this core principle of scientific inquiry. This tension is at the heart of venture due diligence for any data-driven health innovation. We must evaluate if a company's claims are "scientific enough" to be credible, even when the data itself is a closely guarded secret. The investor's dilemma: trust vs. transparency On one hand, a startup's proprietary data is its most valuable asset. It underpins a unique algorithm, a novel diagnostic tool, or a new therapeutic approach. Demanding full public disclosure of this data would be a non-starter; it would destroy the company's competitive advantage. On the other hand, without transparency, we lose the fundamental mechanisms of scientific validation outlined by King et al.: 1. Replicability; 2. Peer review; 3. Uncertainty assessment This creates a high-stakes information asymmetry where investors and potential partners must take a leap of faith. At today’s research design method session, Professor Stephen Linder, Professor Aanand D. Naik, M.D. , and Professor Stephanie Silveira guided a group of fellow researchers at The University of Texas Health Science Center at Houston (UTHealth Houston) to discuss the research design nuances between qualitative, quantitative, and mixed methods approaches, I brought up this question, and some insightful takeaways and recommendations sound realistic and practical to me. A recommended solution: To resolve this, it is considerable to adopt a modified standard for "scientific" credibility that focuses on what can be made public without compromising the core IP. The diligence process shall be designed to push for maximum transparency on the METHODOLOGY, rather than the raw data itself. This aligns with a comment from Professor Stephen Linder, who noted that "the methodology should be disclosed to the public, which could be one way to evaluate how 'scientific' it is and if it is scientific enough". In essence, if the startup's research is a black box, we need to have a white-box explanation of its internal workings. The credibility of the research lies not in the public availability of the data, but in the replicability and rigor of the underlying scientific process and methodology. This approach allows investors and founders to make alignment based on authentic and accountable scientific findings. 

10

Exciting advancements in gene editing, spearheaded by UC Berkeley's Jennifer Doudna and her pioneering CRISPR research, are transforming the landscape. The CRISPR-based gene editing market is projected to reach approximately $4.5 billion in 2025, marking a remarkable 30% year-over-year increase. Forecasts indicate a substantial growth potential, with estimates soaring to $13-16 billion by 2034 at a consistent 25-30% compound annual growth rate. Globally, over 332 companies, with 217 based in the US, are driving innovation in 23 countries. Clinical trials, numbering around 250, with over 150 currently active, are focusing on diverse areas from blood disorders to rare diseases, showcasing impressive success rates ranging from 50-90% in experimental settings. Key developments in 2025, building upon Doudna's foundational work at Cal, include the introduction of personalized CRISPR infusions for treating rare childhood disorders, enhanced editing tools to minimize off-target effects, and RNA delivery techniques for repairing neurons in ALS cases. Biotechnology leads the adoption curve at approximately 40%, with academia and pharmaceutical sectors following suit. #CalGeneEditing #CRISPR #UCBerkeley #LifelongLearning

12

I was honored to contribute insights to this piece on San Diego's biotech ecosystem—a market I've watched evolve significantly over 27 years in healthcare and life sciences. The article features 11 powerhouse companies, from Illumina and Thermo Fisher to emerging leaders like Element Biosciences and Crinetics. But beyond the profiles, it captures something essential about what makes San Diego different. Three observations from the ground: 1. Density without bureaucracy. The Mesa creates a true innovation corridor—UC San Diego, Salk, Scripps Research, and Sanford Burnham Prebys interweave with startups and scaled biopharma. This proximity reduces friction for diligence, talent recruitment, and specialized services in ways Boston and the Bay Area can't replicate. 2. Science-led, but transaction-optimized. San Diego has evolved from "discovery-first" to a complete company-building engine. Teams now design programs around pivotal endpoints, clean CMC plans, and partner-ready data packages earlier. Good science doesn't just get published here—it gets built. 3. Capital is increasingly earned. We're seeing more structured financing (tranched rounds, milestone-based pay-ins), CVRs, and hybrid collaborations. Strategic partners underwrite risk more explicitly. The winning teams treat capital strategy as a product—staging proof points and designing deal structures that preserve upside while de-risking 12-24 months out. Looking ahead, I expect San Diego's next growth phase to be defined by modality-driven oncology, neuroscience/neurodegeneration, precision immunology, and industrial-strength enabling platforms. The market increasingly rewards companies that combine compelling biology, manufacturability, and a partner-ready clinical narrative. I hope you find the article worth a read, especially if you're tracking West Coast biotech or thinking about where innovation capital flows most efficiently. #Biotech #LifeSciences #SanDiego #Innovation #InvestmentBanking #Dealmaking #Healthcare

96

4 Comments

Much of the money and time in healthcare happens past the point of diagnosis. The money: $200B of spend on specialty drugs. The time: putting patients on therapies requires clinical judgment, and navigating a labyrinth of paperwork and people. The result is a byzantine status quo where patients get life saving therapies denied or delayed, and hospital systems capture only $80B of the $200B of drug spend that they originate. Latent’s groundbreaking clinical AI is a portal into the future. Patients get therapies quickly with personalized care, and hospitals transform their bottom line. As a result, Latent has seen extraordinary traction, working with over 50% of the top 20 U.S. health systems in under a year. Latent is one of the biggest and most strategic opportunities in healthcare, sitting in between providers, payors, patients, and pharma. Spark Capital is delighted to support Rishabh Jain and Sriram Somasundaram and this consequential company and to work with Sarah Guo and Michael Dixon.

68

Interesting developments lately around two companies in infinitas capital's and Korify Capital's portfolio, highlighting the renewed momentum in CNS and mental health therapeutics. Alto Neuroscience today announced a $120M private placement financing, providing significant capital to advance its precision psychiatry pipeline, which aims to match patients with treatments using biomarker-driven approaches. At the same time, Bloomberg (link in comments) reported that ATAI Life Sciences AG (ataiBeckley) is exploring strategic options for its lead psychedelic program BPL-003, including a potential partnership or sale that could value the asset at $2B+ as it moves into Phase 3 trials for treatment-resistant depression. Taken together, this reinforces two broader trends we are seeing in the market: 🧠 CNS is moving back to the top of pharma’s strategic agenda, particularly with a significant patent cliff approaching later this decade 💊 Psychedelic therapies are increasingly attracting interest from large pharmaceutical companies, as the clinical data continues to improve and regulatory pathways become clearer With enormous unmet need in mental health and multiple innovative approaches now reaching later clinical stages, neuroscience could become one of the most active biotech sectors in this cycle. #Biotech #Neuroscience #CNS #Psychedelics #BiotechInvesting

44

6 Comments

Lila Sciences has raised $235M in its first financing round backed by Flagship Pioneering. Their mission? To create a fully autonomous science engine that generates hypotheses, runs experiments, and learns — all without human intervention. While many biotech moonshots focus on verticals like drug discovery, Lila's ambition stretches across biology: from therapeutics to materials science, agriculture, and energy. A true multi-domain bet on what AI + automation could unlock for human progress. It’s an exciting time for founders rethinking the scientific method itself. Curious to see what founders and investors in Japan will build next in this direction. Read more: https://lnkd.in/gzt_yyGE #DeepTech #Biotech #AIinScience #AutonomousResearch #FlagshipPioneering #LilaSciences #VentureCapital #StartupFunding

16

1 Comment

Synthesize Bio have launched with a $10M seed round led by Madrona, with support from Sahsen Ventures, LLC, Inner Loop Capital, Point Field Partners, and AI2 Incubator. The Seattle-based startup is building biological foundation models with generative AI to accelerate drug discovery. 🤖 𝐓𝐡𝐞𝐢𝐫 𝐦𝐨𝐝𝐞𝐥𝐬 𝐚𝐢𝐦 𝐭𝐨: - Streamline the identification of high-confidence drug targets. - Simulate therapeutic responses. - Optimize clinical trial design. 🙌 Congratulations to Robert Bradley and the team and make sure you follow their journey with growth almost certain to follow. #AI #Bioinformatics #DrugDiscovery

5

🧬 Programmable Biology is coming! 🧬 “I saw extraordinary software and hardware built to support Mechanical and Electrical engineers, but not Biologists. We were being sold equipment that costs 10x what it should, and performed 1/10th of what we needed.” — Roya Amini-Naieni, co-founder & CEO of Trilobio That’s the gap Trilobio is closing—and why programmable biology is finally getting the tooling it deserves. Trilobio isn’t just automating labs. It’s rethinking how biology gets done. Robotic workcells that run experiments end-to-end. Software that scientists (not just programmers) can actually use. And a platform that helps the same team run 10x more experiments, without burnout. This is the future of synthetic biology—and it’s being built by Roya and Max. If you care about the future of biotech, bookmark Trilobio. 🚀 Read more: https://lnkd.in/gNJvxevJ

12

1 Comment

HeartBeam’s Deep Learning Algorithms Demonstrate High Rates of Accuracy for Detecting Arrhythmias 1) New study presented at HRX Live 2025 demonstrates continued advancement of company’s AI program 2). HeartBeam's AI algorithm performed equally well on HeartBeam 3D ECG system and standard 12L ECGs in classifying atrial fibrillation, atrial flutter and sinus rhythm 3) Deep learning algorithms to be used for future FDA submissions to enhance product offerings HeartBeam Inc. (NASDAQ: BEAT) Heart Rhythm Society American Heart Association

23

Proud of my friends Jared Conley, MD, PhD and Mike Senter-Zapata, MD and the entire team behind this important study with Mass General Brigham and Avo. This work meaningfully advances how we think about reducing cognitive burden for clinicians in emergent situations through true digital co-pilot approaches. Emergent care is fundamentally a cognitive challenge. The difficulty goes beyond the medicine itself. It’s the mental bandwidth required to track a deteriorating patient, keep the team aligned, and make the right call under real pressure. What Jared and colleagues explored is a question we should all be asking: How much better could rapid responses be if we systematically offloaded cognitive load to software that guides, clarifies, and standardizes in real time? Their study offers three core principles: 1. Lower cognitive load → higher clinical performance Physicians across training levels reported less stress, more structure, and higher perceived quality of care when using mobile, condition-specific pathways. This is the essence of a digital co-pilot: elevating the clinician’s judgment by reducing decision friction. 2. UX must match clinical experience One of the most insightful findings: PGY-2 residents rated navigation more difficult than senior attendings. The takeaway is clear — interfaces designed for experts can overwhelm novices. A true co-pilot must adapt to the operator’s cognitive state and experience level, especially when seconds matter. 3. Standardization makes care better These digital checklists, modeled after aviation safety, created a shared mental model across teams. In environments where fragmentation can cost lives, standardization becomes a force multiplier. This work goes far beyond rapid responses. It points to what the next generation of clinical support should look like. We’re already seeing parts of this take shape across the system: Avo — guiding clinicians through critical care in real time Bayesian Health — flagging deterioration early enough to change outcomes Aidin — cutting through the administrative fog that slows transfers Koda Health — removing uncertainty around a patient’s wishes before it reaches the bedside Different problems, different settings, but the same underlying idea: when you take cognitive burden off clinicians, the quality of care goes up. The term “co-pilot” only means something if the tool shows up the way clinicians do in tough moments — steady, useful, and out of the way. Jared and the team have produced an example of what that future can look like. Our healthcare system needs a lot more of this kind of work. https://lnkd.in/gWZ5PA5c?

67

3 Comments